Literature DB >> 3759252

[Imipenem/cilastatin in surgical intensive medicine].

H Wenk, H Schier, H Hollandt, A Valesky.   

Abstract

26 patients from the surgical intensive care unit, University Hospital Lübeck, received imipenem/cilastatin for severe abdominal, respiratory or urogenital infections. 500 mg imipenem/cilastatin were infused i.v. over 30 min q. i. d. The treatment was successful in 84,6% of the patients suffering from severe infections. Two cases were considered to be failures. 36 of the 43 isolated pathogens (83.7%) were eliminated. Transitory elevations of liver enzymes were the most frequent side-reactions observed; an increase in serum creatinine, diarrhoea or fungal colonization were less common.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3759252     DOI: 10.1007/bf01647504

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  4 in total

1.  Multiple-dose pharmacokinetics of imipenem-cilastatin.

Authors:  G L Drusano; H C Standiford; C Bustamante; A Forrest; G Rivera; J Leslie; B Tatem; D Delaportas; R R MacGregor; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

2.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

3.  Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.

Authors: 
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

4.  Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients.

Authors:  B A Zajac; M A Fisher; G A Gibson; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.